Voglibose
Voglibose structure
|
Common Name | Voglibose | ||
|---|---|---|---|---|
| CAS Number | 83480-29-9 | Molecular Weight | 267.276 | |
| Density | 1.6±0.1 g/cm3 | Boiling Point | 601.9±55.0 °C at 760 mmHg | |
| Molecular Formula | C10H21NO7 | Melting Point | 162-163ºC | |
| MSDS | Chinese USA | Flash Point | 274.1±22.1 °C | |
|
Intensive glucose lowering in cardiovascular risk management - unsolved questions - .
Circ. J. 76(3) , 593-5, (2012)
|
|
|
Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients.
Circ. J. 76(3) , 712-20, (2012) Postprandial hyperglycemia and hyperinsulinemia have been considered as important determinants for the development of atherosclerosis. However, it remains to be elucidated whether correction of the postprandial glycemic status prevents atherosclerotic changes... |
|
|
Effect of voglibose on the pharmacokinetics of metformin in healthy Korean subjects.
Int. J. Clin. Pharmacol. Ther. 52(11) , 1005-11, (2014) The objective of this study was to evaluate the effects of voglibose on the pharmacokinetics of metformin.A randomized, open-label, two-way crossover study with a 7-day washout period was conducted. All subjects were given an oral dose of metformin with or wi... |
|
|
Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
Cardiovasc. Diabetol. 14 , 83, (2015) Left ventricular (LV) diastolic dysfunction is frequently observed in patients with type 2 diabetes. Dipeptidyl peptidase-4 inhibitor (DPP-4i) attenuates postprandial hyperglycemia (PPH) and may have cardio-protective effects. It remains unclear whether DPP-4... |
|
|
Influence of an antidiabetic drug on biomechanical and histological parameters around implants in type 2 diabetic rats.
Implant Dent. 23(3) , 264-9, (2014) Type 2 diabetes mellitus (DM) has a deleterious effect on dental implant integration into alveolar bone, thought to arise from impaired osteoblast function and consequent reduced bone turnover. However, whether controlling blood glucose with antidiabetic drug... |
|
|
Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.
Clin. Exp. Pharmacol. Physiol. 42(1) , 87-93, (2014) Inhibition of sodium-glucose cotransporter 2 is a novel strategy for glycemic control in type 2 diabetes mellitus patients. As the mechanism of action of sodium-glucose cotransporter 2 inhibitors on plasma glucose levels is distinct from that of existing oral... |
|
|
Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus.
Expert Opin. Pharmacother. 14(4) , 361-70, (2013) We examined the effects of a fixed-dose combination of 10 mg mitiglinide and 0.2 mg voglibose on postprandial glycemic excursions in Japanese type 2 diabetes mellitus (T2DM) patients.After a 2-week baseline period, 11 T2DM patients were treated with mitiglini... |
|
|
Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus.
Expert Opin. Pharmacother. 13(16) , 2257-68, (2012) The objective of this study was to compare the effects of mitiglinide, voglibose and its combination on metabolic responses after a test meal in Japanese patients with type 2 diabetes mellitus (T2DM).This randomized crossover study consisted of four periods b... |
|
|
Intestinal alpha-glucosidase inhibitors: abdominal gas cysts.
Prescrire Int. 21(130) , 212-3, (2012) Detailed imaging studies of gas cysts in the intestinal mucosa (pneumatosis cystoides intestinalis) have been reported in around 20 patients taking acarbose, miglitolor voglibose, i.e. intestinal alpha-glucosidase inhibitors used as hypoglycaemic agents. Almo... |
|
|
Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
J. Am. Heart Assoc. 2(1) , e003277, (2013) Endothelial dysfunction is an independent predictor for cardiovascular events in patients with type 2 diabetes (T2DM). Glucagon like peptide-1 (GLP-1) reportedly exerts vasodilatory actions, and inhibitors of dipeptidyl peptidase-4 (DPP-4), an enzyme-degradin... |